Biocad has announced plans to begin shipping the firm’s biosimilar of Janssen’s Remicade (infliximab) to “global markets” towards the end of this year, or in early 2019.
Biocad has announced plans to begin shipping the firm’s biosimilar of Janssen’s Remicade (infliximab) to “global markets” towards the end of this year, or in early 2019.
“India, where the market for infliximab amounted to US$42 million in 2017, is expected to be the first country to...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
